NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Biotechnology

Healthcare
$19.74 +0.39%

+$0.12 today

Market cap
$2.37B
Beta
0.08
P/E (TTM)
-17.2
EPS (TTM)
-$1.76
52W Low $17.63High $42.21

Volume 1.80M

Average 1.21M

NAMS Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

NewAmsterdam Pharma Company N.V.NASDAQ: NAMS

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q2 FY2026 weighted avg shares (diluted) of 123.37M shares rose 9.7% year over year, behind the +13.7% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 1.9% from the prior quarter. Over 3 fiscal years it compounded at +82.0% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +9.7% toward the trailing-twelve-month pace of +13.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
123.37M+1.9% QoQ
Last fiscal yearDec 2025
114.4M+21.2% YoY
LTMJun 2026
119.47M+13.7% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.7%——
1 year+21.2%——
3-year CAGR+82.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
114.4M USD
Year-over-year change
+21.2%
4-year CAGR
+59.3%

Weighted Avg Shares (Diluted) vs competitors

How NAMS compares with its peers on the latest reported figures

  • NAMS's LTM Jun 2026 weighted avg shares (diluted) of 119.47M shares is the 2nd highest of the 9 companies compared; the peer median is 53.24M shares.
  • Its year-over-year change of +13.7% is the 4th highest of 9, against a peer median of +8.1%.
  • Over three fiscal years its annual growth of +82.0% compares with a peer median of +12.4%.
NAMS Competitors Peer median
Weighted Avg Shares (Diluted) for NAMS and competitors
Company Period LTM YoY 3-year CAGR
DNLIDenali Therapeutics Inc.LTM Jun 2026180.46M +5.8%+11.8%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026119.47M +13.7%+82.0%
VKTXViking Therapeutics, Inc.LTM Jun 2026114.45M +2.5%+13.6%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026108.82M +29.3%+12.4%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 202661.23M +1.8%+14.3%
SEPNSepterna, Inc.LTM Sep 202645.24M +9.0%—
BIOABioAge Labs, Inc.LTM Mar 202637.57M +7.3%+1.7%
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 202625.77M +17.2%+9.4%
ATHEAlterity Therapeutics LimitedFY202510.66M +75.3%+38.5%
Peer median (excluding NAMS) 53.24M+8.1%+12.4%

Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0102.69M14.09M45.56M22.5M
Cost of Revenue000059K
Gross Profit0102.69M14.09M45.56M22.44M
Gross Margin—100.0%100.0%100.0%99.7%
Research & Development28.97M86.74M159.42M151.41M141.83M
Selling, General & Admin5.68M19.51M37.63M70.45M106.3M
Operating Expenses34.98M106.25M197.06M221.85M248.13M
Depreciation & Amortization5K9K49K113K220K
EBITDA(41.37M)(22.34M)(176.86M)(241.49M)(242.33M)
EBITDA Margin—-21.8%-1255.2%-530.0%-1076.9%
Operating Income(34.98M)(3.56M)(182.97M)(176.29M)(225.68M)
Operating Margin—-3.5%-1298.6%-386.9%-1002.9%
Interest Income0010.22M16.88M27.59M
Interest Expense411K287K6.8M00
Other Income / Expenses(6.81M)(19.08M)6.06M(65.31M)21.86M
Income Before Tax(41.79M)(22.63M)(176.91M)(241.6M)(203.82M)
Pre-Tax Margin—-22.0%-1255.6%-530.3%-905.7%
Income Tax Expense0027K(1K)0
Net Income(41.79M)(22.63M)(176.94M)(241.6M)(203.82M)
Net Margin—-22.0%-1255.8%-530.3%-905.7%
EPS (Basic)(3.34)(1.19)(2.15)(2.56)(1.75)
EPS (Diluted)(3.34)(1.19)(2.15)(2.56)(1.75)
Weighted Avg Shares17.75M18.97M82.16M94.36M114.4M
Weighted Avg Shares (Diluted)17.75M18.97M82.16M94.36M114.4M

NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Intrinsic Alpha fair value

Locked

Current Price

$19.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.